Rodan + Fields has offered to pay $38 million to resolve several class action lawsuits surrounding its Lash Boost product, a serum advertised to dramatically increase lash length and density.
 
Plaintiffs in three class action lawsuits say that Lash Boost is actually a misbranded drug that can cause serious side effects. They specifically challenge the ingredient isopropyl cloprostenate, a prostaglandin analog—a type of chemical used in glaucoma treatments. Due to this drug ingredient, plaintiffs argue that Lash Boost should be regulated by the FDA and treated as a drug instead of an untested cosmetics product.
 
According to the Lash Boost class action lawsuits, Rodan + Fields customers unknowingly used this medical drug near their eyes and put themselves at risk for adverse reactions such as eye irritation, macular edema, iris color change, and ocular inflammation.
 
Furthermore, plaintiffs allege that the inclusion of isopropyl cloprostenate contradicts Rodan + Fields’ marketing promises that Lash Boost is “not a drug product,” “contains only cosmetic ingredients,” and is “not associated with any significant side effects.”
 
Rodan + Fields didn’t admit any wrongdoing but agreed to pay $38 million to resolve three Lash Boost class action lawsuits.
 
Under the terms of the Lash Boost class action settlement, Class Members can collect either a cash payment or a credit voucher.
 
In addition to providing cash, Rodan + Fields has agreed to make Lash Boost label changes to revise instructions, warnings and other information.